Target Name: MLANA
NCBI ID: G2315
Review Report on MLANA Target / Biomarker Content of Review Report on MLANA Target / Biomarker
MLANA
Other Name(s): MAR1_HUMAN | Melanoma antigen recognized by T-cells 1 | melan-A | Antigen SK29-AA | antigen LB39-AA | MART-1 | Melan-a | protein Melan-A | antigen SK29-AA | Protein Melan-A | MART1 | Antigen LB39-AA | Melan-A | epididymis secretory sperm binding protein

MLANA: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease that affects the central nervous system. It is characterized by the immune system attacking the protective covering of nerve fibers, leading to the displacement of nerve signals and a range of symptoms, including muscle weakness , vision problems, and fatigue.

Currently, scientists have discovered many biomarkers and potential drug targets related to MS. One popular target is MLANA (MAR1_HUMAN), a gene with high expression in humans. MLANA is not only highly expressed in MS patients but also in different neurodegenerative diseases.

MLANA is a protein encoded by the myelin phospholipid acid (phospholipid acid) gene. In humans, MLANA is expressed at higher levels, especially in the brain and spinal cord. It is highly expressed in MS patients and correlates with disease activity and severity. In addition, MLANA is also expressed in different neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.

In order to further study the application of MLANA in MS, scientists conducted a large number of experiments. They found that MLANA could serve as a biomarker for MS and could be used to assess disease activity and severity. In addition, MLANA can also serve as a potential drug target for the treatment of MS and other neurodegenerative diseases.

Currently, MLANA has become the target of multiple MS drug research and development projects. Scientists are exploring how MLANA interacts with MS-related immune cells and neurons and how these interactions can be exploited to develop new MS treatment strategies. They also studied the safety of MLANA in the preclinical stage of the drug and discovered the interactions between MLANA and other drugs, which provided an important theoretical basis for the drug development of MLANA.

In addition to serving as a biomarker and potential drug target for MS, MLANA serves as a new way to study neurodegenerative diseases. Scientists can use MLANA to study the development of neurodegenerative diseases, the role of factors that influence neurodegenerative diseases, and to uncover new treatment strategies.

In short, MLANA, as a gene with high expression in humans, has broad application prospects. In-depth study of the application of MLANA in MS and other neurodegenerative diseases can provide an important theoretical basis for the development of new treatment strategies. With the deepening of MLANA research, we are expected to see MLANA as a drug target to bring health and happiness to humans.

Protein Name: Melan-A

Functions: Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes

The "MLANA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MLANA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A | MOB3B | MOB3C | MOB4 | MOBP | MOCOS | MOCS1 | MOCS2 | MOCS2-DT | MOCS3 | MOG | MOGAT1 | MOGAT2 | MOGAT3 | MOGS | MOK | MON1A